Sarvari Yellapragada, MD

Article

RVD With Weekly Bortezomib Has a Favorable Toxicity and Effectiveness Profile in a Large Cohort of US Veterans With Multiple Myeloma

Author:: Maxwell M. Krem, MD, PhD; June K. Corrigan, MS; Sarvari Yellapragada, MD; Joseph G. Bennett, MD; Nhan V. Do, MD; Mary T. Brophy, MD; Nikhil C. Munshi, MD; Daphne R. Friedman, MD; Nathanel R. Fillmore, PhD

Read More

Article

The First Patient in the Veteran Affairs System to Receive Chimeric Antigen Receptors T-cell Therapy for Refractory Multiple Myeloma and the Role of Intravenous Immunoglobulin in the Prevention of Therapy-associated Infections

Author:: Trung Nguyen, MD; Christi Swierenga, MSN, AOCNP:,; MSN; RN; Wichai Chinratanalab, MD; Stephen Cernawsky, ACNP-BC; Jana Sawyer, PharmD; Kendall Shultes, PharmD, BCOP; Rhonda Williams, DNP, FNP-C; John Mbue, PharmD, BCOP; Sarvari Yellapragada, MD

Read More

Article

The First Female Patient in the Veteran Affairs System to Receive Chimeric Antigen Receptors (CAR) T-cell Therapy for Refractory Multiple Myeloma and the Role of CAR T-cell Therapy in Penta-refractory Disease

Author:: Rosa Torres Ramos, AOCNP-BC; Rexy Rajan, MSN, RN; Salyka Sengsayadeth, MD; Donna Dunn, NP; Jana Sawyer, PharmD; Kendall Shultes, PharmD, BCOP; Rhonda Williams, DNP, FNP-C; Richard Gremillion, PharmD, MS, BCOP; Trung Nguyen, MD; Sarvari Yellapragada, MD

Read More